HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) Director Aditya Kohli sold 723 shares of the company's stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $14.15, for a total value of $10,230.45. Following the completion of the sale, the director now owns 782,878 shares in the company, valued at approximately $11,077,723.70. The transaction was disclosed in a filing with the SEC, which is available at this link.
Aditya Kohli also recently made the following trade(s):
- On Wednesday, May 1st, Aditya Kohli sold 175 shares of HilleVax stock. The stock was sold at an average price of $14.03, for a total value of $2,455.25.
- On Friday, April 5th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $14.44, for a total value of $86,640.00.
- On Wednesday, April 3rd, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $14.93, for a total transaction of $89,580.00.
- On Wednesday, March 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $164,221.00, for a total transaction of $985,326,000.00.
- On Monday, March 18th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $17.66, for a total value of $105,960.00.
- On Friday, March 8th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $18.66, for a total value of $111,960.00.
- On Wednesday, March 6th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $18.95, for a total transaction of $113,700.00.
- On Thursday, February 22nd, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $15.05, for a total value of $90,300.00.
- On Tuesday, February 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.88, for a total value of $89,280.00.
- On Monday, February 12th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $15.32, for a total value of $91,920.00.
HilleVax Price Performance
Look Who Fired the World’s Richest Man
From Banyan Hill Publishing | Ad
This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S.
And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.
Get the full story here.
HLVX opened at $13.61 on Friday. The firm has a market cap of $676.69 million, a price-to-earnings ratio of -4.48 and a beta of 0.79. The company has a current ratio of 10.62, a quick ratio of 10.62 and a debt-to-equity ratio of 0.10. The stock's 50-day moving average price is $15.62 and its 200 day moving average price is $14.66. HilleVax, Inc. has a 12-month low of $9.94 and a 12-month high of $20.22.
HilleVax (NASDAQ:HLVX - Get Free Report) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.02. As a group, sell-side analysts expect that HilleVax, Inc. will post -3.22 earnings per share for the current year.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and issued a $28.00 price target on shares of HilleVax in a research note on Thursday, March 21st.
Check Out Our Latest Stock Analysis on HilleVax
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. boosted its stake in HilleVax by 80.6% in the third quarter. Federated Hermes Inc. now owns 2,113 shares of the company's stock valued at $28,000 after acquiring an additional 943 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of HilleVax in the 4th quarter valued at about $139,000. Seven Grand Managers LLC acquired a new stake in shares of HilleVax in the 3rd quarter valued at about $200,000. abrdn plc purchased a new position in HilleVax during the 4th quarter worth approximately $433,000. Finally, Swiss National Bank grew its stake in HilleVax by 47.2% during the 3rd quarter. Swiss National Bank now owns 31,200 shares of the company's stock worth $420,000 after buying an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 86.42% of the company's stock.
HilleVax Company Profile
(
Get Free Report)
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
